Biogen Idec rumored to be interested in Genmab… Will GSK move in?

According to The Times of London, the rumor is that Biogen Idec (NASDAQ:BIIB), which tried but failed to sell itself last year at the prompting of the activist shareholder Carl Icahn, may be pondering a bid for Genmab (Copenhagen:GEN.CO), a  $ 4 billion Danish American biotech group witha rich Monoclonal Antibody pipeline . GlaxoSmithKline (NYSE:GSK) has the licence for HuMax, a leukaemia treatment, and committed over $ 2 billion to Genmab last year. We would not be surprised if GSK decided to counterbid to protect its position.